Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.\DE is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious and rare diseases. The company focuses on therapeutic areas where existing treatments can be improved in terms of effectiveness, safety, or ease of dosing. Viridian aims to create differentiated medicines that could lead to better patient outcomes, fewer side effects, improved quality of life, and broader market access. Its pipeline targets established biological pathways and disease mechanisms in autoimmune and rare diseases. This includes product candidates for the insulin-like growth factor 1 receptor (IGF-1R) to treat thyroid eye disease (TED), inhibitors of the neonatal Fc receptor (FcRn) for various autoimmune disorders, and a TSHR inhibitor program with potential applications in TED and Graves' disease. Viridian develops therapeutics through internal research and discovery, as well as by licensing opportunities that align with its strategy. The company's capabilities cover protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization in these therapeutic areas. As it prepares for the potential launch of its first commercial product, if approved, Viridian is building infrastructure for sales and marketing, market access, patient services, and commercial operations, while expanding its medical, clinical, regulatory, quality, and supply chain and distribution capabilities.